Navigation Links
Bone marrow transplant eliminates signs of HIV infection
Date:7/26/2012

Boston, MA Two men with longstanding HIV infections no longer have detectable HIV in their blood cells following bone marrow transplants. The virus was easily detected in blood lymphocytes of both men prior to their transplants but became undetectable by eight months post-transplant. The men, who were treated at Brigham and Women's Hospital (BWH), have remained on anti-retroviral therapy. Their cases will be presented on July 26, 2012 at the International AIDS Conference by Timothy Henrich, MD and Daniel Kuritzkes, MD, physician-researchers in the Division of Infectious Diseases at BWH.

"This gives us some important information", said Dr. Kuritzkes. "It suggests that under the cover of anti-retroviral therapy, the cells that repopulated the patient's immune system appear to be protected from becoming re-infected with HIV."

One patient's bone marrow transplant was two years ago, the other was four years ago. Both were performed at the Dana-Farber/Brigham and Women's Cancer Center. Over time, as the patients' cells were replaced by donor cells, traces of HIV were lost. Currently, both patients have no detectable HIV DNA or RNA in their blood. The level of HIV antibody, a measure of exposure to HIV, also declined in both men.

"We expected HIV to vanish from the patients' plasma, but it is surprising that we can't find any traces of HIV in their cells", said Dr. Henrich. "The next step is to determine if there are any traces of HIV in their tissue."

The research team is currently designing studies that would enable them to look for HIV in the tissues. Researchers also plan to study additional HIV-positive patients who have undergone a bone marrow transplant.

Researchers point out that there are two key differences between the Brigham patients and the "Berlin patient", a man who was functionally cured of HIV after a stem cell transplant. In the Berlin patient's case, his donor was specifically chosen because the donor had a genetic mutation that resisted HIV. The Brigham patients' bone marrow transplants were done without any thought to selecting an HIV-resistant donor. Second, the Berlin patient ceased anti-retroviral therapy after his transplant, while the Brigham patients have remained on anti-retroviral therapy.


'/>"/>
Contact: Tom Langford
tlangford@partners.org
617-534-1605
Brigham and Women's Hospital
Source:Eurekalert

Related medicine news :

1. Fertilizing bone marrow helps answer why some cancers spread to bones
2. Markey receives $6.25 million to study deadly blood and bone marrow disease
3. HIV Drug May Prevent Bone Marrow Transplant Complication
4. HIV drug reduces graft-vs.-host disease in bone marrow transplant patients, Penn study shows
5. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
6. Discovery could help to develop drugs for organ transplant and cancer patients
7. Xenotransplantation as a therapy for type 1 diabetes
8. First, Second Kidney Transplants Have Similar Success: Study
9. Lenalidomide prolongs disease control for multiple myeloma patients after stem cell transplant
10. Statins prevent cancer in heart transplant recipients
11. U.S. Liver Transplants Declining
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
(Date:1/17/2017)... ... January 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New ... the region, is launching a charity drive to raise awareness of heart disease and ... killer in America, and is responsible for 1 in every 4 deaths at the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
(Date:1/17/2017)... Tyler, TX (PRWEB) , ... January 17, 2017 ... ... serving Texas families from two offices in Tyler, has announced the latest beneficiary ... Red Ribbon Wish Network, a nonprofit organization dedicated to fulfilling the dreams of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene ... vice president, research and pharmaceutical development at Tocagen, will present at ... held Jan. 17-20 in Miami . ... ... manufacturing for replicating viruses - what to do when and why ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
(Date:1/17/2017)... , Jan. 17, 2017 Immune Pharmaceuticals (NASDAQ: ... company, announced today that it will hold a Satellite Symposium ... Acute Leukemias (ISAL) XVI in Munich, Germany ... "Reinforcing the Efficacy of Immunotherapy for the maintenance of ... on Monday February 20 th , 2017 from 12:45 – ...
Breaking Medicine Technology: